Oncology Vol 28 No 2

The Utility of Molecular Testing in Colorectal Cancer: The Promise Needs Progress

February 15, 2014

Molecularly profiling colorectal cancer has opened many potential opportunities for the use of this information in therapeutic decision-making. However, at present, only RAS testing in the metastatic setting has a definitive place in the decision-making paradigm.

Improving the Early Detection of Prostate Cancer: A Balancing Act

February 15, 2014

Improved early detection of prostate cancer would ideally involve a noninvasive test that allows clinicians to distinguish aggressive cancers from relatively indolent ones. This distinction is especially important given that relatively few men who undergo screening are destined to die of prostate cancer.

Precision Medicine Approaches to the Diagnosis and Management of Prostate Cancer

February 15, 2014

For those undergoing screening for the presence of previously undiagnosed prostate cancer, the major challenge for new tests is to avoid the overdetection of indolent cancers that limits the clinical utility of the prostate-specific antigen (PSA) test.

Baseline PSA Testing for Men in Their 40s: Currently Available Evidence Strongly Supports Baseline PSA Measurements in This Age Group

February 15, 2014

The benefit-to-risk trade-offs associated with PSA screening are highly sensitive to patient preference, underscoring the importance of ensuring that men have the opportunity to decide for themselves whether they wish to have their individual risk for suffering and death from prostate cancer assessed through PSA screening.

Personalized Medicine and Anti-EGFR Antibody Therapy in the Treatment of Metastatic Colorectal Cancer: KRAS and Beyond

February 15, 2014

It was originally hoped that the presence of mutations in KRAS and other related genes would provide an easy answer as to whether to administer anti-EGFR antibody therapy to a given metastatic colorectal cancer patient. However, in nature nothing is simple, and there are a number of issues that practicing clinicians should be made aware of.

New Biomarkers in Prostate Cancer

February 15, 2014

In this article, we review recent advances in the discovery of prostate cancer biomarkers, their integration into clinical practice, and implications for improving clinical management of the disease.